Scarica l'app Stockscreener
0.21
0.96%
0.002
Dopo l'orario di chiusura:
.21
Precedente Chiudi:
$0.208
Aprire:
$0.209
Volume 24 ore:
4.38M
Relative Volume:
0.82
Capitalizzazione di mercato:
$17.77M
Reddito:
$297.50K
Utile/perdita netta:
$-72.19M
Rapporto P/E:
-0.1226
EPS:
-1.7127
Flusso di cassa netto:
$-54.39M
1 W Prestazione:
-37.54%
1M Prestazione:
-51.53%
6M Prestazione:
-78.35%
1 anno Prestazione:
-83.72%
Intervallo 1D:
$0.1985
$0.232
Intervallo di 1 settimana:
$0.1611
$0.37
Portata 52W:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.21 | 17.60M | 297.50K | -72.19M | -54.39M | -1.7127 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics closes $5 million stock offering By Investing.com - Investing.com Australia
Published on: 2026-03-26 16:05:05 - baoquankhu1.vn
Outlook Therapeutics Announces $500,000 Public Offering of Common Stock and Warrants - Minichart
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants - TipRanks
Outlook Therapeutics closes 5.0 million dollar public offering to boost capital - Traders Union
Outlook Therapeutics commences $5.0M best-efforts offering of common stock with 1-for-1 warrants - TradingView
[8-K] Outlook Therapeutics, Inc. Reports Mat... - Stock Titan
Outlook Therapeutics closes $5 million stock offering - Investing.com
Outlook Therapeutics sells 20M shares, closes $5M financing - Stock Titan
Outlook Therapeutics (OTLK) launches 20M-share offering with detachable warrants - Stock Titan
Outlook Therapeutics prices $5M stock offering at $0.25 per share - Investing.com Australia
Outlook Therapeutics stock prices $5M offering at $0.25 per share amid Nasdaq plunge and biotech fun - AD HOC NEWS
Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced - marketscreener.com
Why is OTLK stock falling today? - MSN
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
20M new shares at 25 cents: Outlook prices $5M fundraise - Stock Titan
Why Is OTLK Stock Falling Today? - Stocktwits
Biggest stock movers Tuesday: CLB, OTLK, and more (NASDAQ:NTGR) - Seeking Alpha
Outlook Therapeutics launches public stock offering By Investing.com - Investing.com Canada
Outlook Therapeutics announces proposed public offering sending shares into focus - Traders Union
Outlook Therapeutics (OTLK) Launches Public Offering, Shares Sli - GuruFocus
Outlook Therapeutics Announces Proposed Public Offering - The Manila Times
Outlook Therapeutics launches public stock offering - Investing.com
Outlook Therapeutics announces proposed public offering - marketscreener.com
Eye-disease drug developer seeks cash in stock-and-warrant sale - Stock Titan
Outlook Therapeutics (OTLK) offers common stock, pre-funded warrants and common warrants - Stock Titan
OTLK Stock Price, Quote & Chart | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
Whale Trades: Is Outlook Therapeutics Inc a top pick in the sector2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Outlook Therapeutics secures $18.4M note, extends debt maturity By Investing.com - Investing.com India
Outlook Therapeutics Faces Substantial Doubt as a Going Concern Amid Funding Shortfall and Ongoing FDA Setbacks for ONS-5010/LYTENAVA 1234567 - Minichart
Outlook Therapeutics, Inc. announced that it has received $18.36 million in funding from Atlas Sciences, LLC - marketscreener.com
Outlook Therapeutics (OTLK) Restructures Debt with New Financing Moves - GuruFocus
Outlook Therapeutics Refinances Debt, Extends Note Maturities - TipRanks
Outlook Therapeutics Secures $17 Million Atlas Note to Refinance Avondale Debt - TradingView
Outlook Therapeutics (OTLK) refinances debt with $18.36M note amid going concern risks - Stock Titan
Outlook Therapeutics announces new $18.4 million non-convertible note financing and amendment to existing convertible note - marketscreener.com
Outlook Therapeutics secures $18.4M note, extends debt maturity - Investing.com
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note - Bitget
Outlook Therapeutics Amends Current Convertible Note With Avondale Capital To Extend Maturity Through Dec. 31; Signs $18.4M New NoteOutlook Therapeutics (NASDAQ:OTLK) - Benzinga
Outlook Therapeutics Announces New $18.4 Million - GlobeNewswire
Options Flow: Can Outlook Therapeutics Inc reach all time highs this year2026 Sentiment & Capital Efficient Trading Techniques - baoquankhu1.vn
Outlook Therapeutics Announces Board Resignation and Size Reduction - The Globe and Mail
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor - The Globe and Mail
Outlook Therapeutics' Dr. Julia Haller resigns from board; size reduced to nine - TradingView
Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026 - marketscreener.com
Outlook Therapeutics (NASDAQ: OTLK) trims board to nine directors - Stock Titan
Ascendiant Capital Lowers Price Target for Outlook Therapeutics (OTLK) | OTLK Stock News - GuruFocus
Shareholders at Outlook Therapeutics (NASDAQ: OTLK) approve board slate - Stock Titan
Outlook Therapeutics discusses FDA meeting on bevacizumab drug - Investing.com Nigeria
Published on: 2026-03-10 21:03:39 - baoquankhu1.vn
Key facts: Outlook Therapeutics Engages FDA on ONS-5010 Approval Pathways - TradingView
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.04%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):